DCHS1

DCHS1 is a large protocadherin that functions as a ligand-receptor partner of FAT4 to control progenitor proliferation, planar cell polarity, and tissue morphogenesis across many developing organs (PMID:21303848). Genetic and protein-stabilization data establish a reciprocal DCHS1-FAT4 relationship, with mutation of either gene altering the other's staining and single and double mutants sharing phenotypes (PMID:21303848). The DCHS1-FAT4 axis acts upstream of the Hippo effector YAP to restrain neural progenitor proliferation and promote differentiation (PMID:24056717), and loss of the axis elevates YAP-TEAD activity, expanding osteoprogenitors and delaying osteoblast differentiation by altering YAP/TAZ-Runx2 complex activity (PMID:31358536); in other tissues, including renal nephron progenitors and developing vertebrae, DCHS1-FAT4 regulation is YAP/TAZ-independent, indicating context-specific signaling outputs (PMID:26116661, PMID:27381226). In parallel, DCHS1-FAT4 drives planar cell polarity, controlling polarized cell intercalation and orientation during sternum and skeletal morphogenesis and tangential neuronal migration (PMID:24998526, PMID:27145737). DCHS1 protein localizes in a polarized manner at the interface between signaling cell populations and is required cell-autonomously for directional FAT4 signaling (PMID:26116666), while the FAT4 intracellular domain controls trans-endocytosis of DCHS1 and actin-dependent boundary accumulation of the complex (PMID:39955614). The DCHS1 intracellular domain is itself essential: its deletion abolishes polarized localization, perturbs neural cell polarity and proliferation, lowers pYAP1:YAP1 ratios, and produces Van Maldergem syndrome-like craniofacial and skeletal phenotypes (PMID:41972678). Mechanistically, the DCHS1 cytoplasmic tail links to the septin-actin cytoskeleton through LIX1L and SEPT9 to organize filamentous actin and direct cell-ECM alignment (PMID:35200715). DCHS1 missense mutations destabilize the protein and cause mitral valve prolapse through valve morphogenesis defects (PMID:26258302).

1. 2011 High

   Established that DCHS1 and FAT4 act as a developmentally coupled ligand-receptor pair rather than independent factors, defining the core axis.

   Evidence Single and double knockout mice with reciprocal immunostaining and shared multi-organ phenotypes

   PMID:21303848

   Open questions at the time

   • Did not resolve which downstream effectors transduce the signal
   • Direct biochemical demonstration of extracellular binding not provided here
2. 2013 High

   Placed the DCHS1-FAT4 axis upstream of YAP, connecting protocadherin signaling to the Hippo pathway in neural progenitor control.

   Evidence In utero knockdown in mouse neuroepithelium with Yap concurrent-knockdown epistasis

   PMID:24056717

   Open questions at the time

   • Molecular link between DCHS1-FAT4 and YAP regulation not defined
   • Whether YAP dependence is universal across tissues unaddressed
3. 2014 High

   Distinguished cell-autonomous from extrinsic requirements and showed DCHS1-FAT4 controls planar cell polarity-driven collective migration along defined axes.

   Evidence Conditional and mosaic Dchs1 inactivation with live imaging of facial branchiomotor neuron migration

   PMID:24998526

   Open questions at the time

   • Cytoskeletal effectors of PCP-driven migration not identified
   • Relationship to Hippo output in this context unclear
4. 2015 High

   Demonstrated that DCHS1 missense mutations cause disease through reduced protein stability, linking DCHS1 to human mitral valve prolapse.

   Evidence Zebrafish morpholino rescue, stability assays in patient MVICs, Dchs1+/- mouse valve histology

   PMID:26258302

   Open questions at the time

   • Mechanism linking valve cell patterning defects to morphogenesis not fully resolved
   • Downstream signaling in valve cells not mapped
5. 2015 High

   Showed DCHS1 polarized localization and cell-autonomous requirement mediate directional stroma-to-cap-mesenchyme FAT4 signaling, and that this branch is YAP-independent.

   Evidence Tissue-specific conditional deletions, genetic double mutants, mosaic antibody staining, EM in kidney

   PMID:26116661 PMID:26116666

   Open questions at the time

   • YAP-independent effector restraining progenitor self-renewal not identified
   • Degree of DCHS1/DCHS2 redundancy in other tissues unknown
6. 2016 High

   Defined an intrinsic PCP role for DCHS1-FAT4 in mesenchyme shaping skeletal form, and confirmed YAP/TAZ-independent proliferation control in vertebrae.

   Evidence Dchs1/Fat4 knockout mice, cell orientation quantification, Fat4;Yap and Fat4;Taz double mutants

   PMID:27145737 PMID:27381226

   Open questions at the time

   • Effector mediating YAP/TAZ-independent proliferation undefined
   • Link between cell orientation and proliferation control unresolved
7. 2019 High

   Connected DCHS1-FAT4 loss to elevated YAP-TEAD activity and altered YAP/TAZ-Runx2 complexes governing osteoblast differentiation.

   Evidence Knockout and conditional Yap/Taz mice, Yap-Tead reporters, Runx2 activity assays, Yap/Taz-Runx2 co-IP

   PMID:31358536

   Open questions at the time

   • How DCHS1-FAT4 mechanistically modulates YAP phosphorylation not shown
   • Direct DCHS1 involvement in Runx2 complexes not demonstrated
8. 2022 Medium

   Identified a cytoplasmic scaffold connecting DCHS1 to the cytoskeleton, providing a mechanism for cell-ECM alignment.

   Evidence Co-IP/pulldown of DCHS1-LIX1L-SEPT9, actin organization assays in mouse and cell models

   PMID:35200715

   Open questions at the time

   • Reciprocal validation and direct binding interfaces not established
   • Single lab; structural basis of the interaction unknown
9. 2025 Medium

   Resolved how the FAT4 intracellular domain drives trans-endocytosis and actin-dependent boundary accumulation of DCHS1-FAT4 complexes.

   Evidence Quantitative live imaging with ICD deletion constructs and actin polymerization inhibition

   PMID:39955614

   Open questions at the time

   • Role of the DCHS1 ICD versus FAT4 ICD in endocytosis not separated here
   • Molecular machinery of trans-endocytosis not identified
10. 2025 Medium

    Characterized DCHS1 proteolytic cleavage and lineage-restricted cardiac expression, indicating intracellular fragment signaling and heterotypic cell bridging.

    Evidence Dchs1-HA knock-in mouse, western blotting, immunohistochemistry, single-cell transcriptomics

    PMID:40497950

    Open questions at the time

    • Function and targets of cleaved C-terminal fragments unknown
    • Protease responsible for cleavage not identified
11. 2026 Medium

    Established that the DCHS1 intracellular domain is required in vivo for polarized localization, polarity, proliferation control, and YAP regulation, and underlies Van Maldergem-like phenotypes.

    Evidence Dchs1Δ ICD-deletion knock-in mouse with immunohistochemistry, Ki67 assays, pYAP1 quantification

    PMID:41972678

    Open questions at the time

    • ICD interactors mediating these effects not enumerated here
    • Single lab; mechanism linking ICD to pYAP1 changes not detailed
12. 2025 Low

    Implicated DCHS1 in human-specific neurodevelopmental allocation via an N-glycosylation change and identified EPHA4 as a candidate binding partner.

    Evidence CRISPR editing of hiPSCs, neural organoids, binding partner identification (preprint)

    PMID:40463223

    Open questions at the time

    • EPHA4 interaction not validated by reciprocal or in vitro binding assay
    • Preprint; mechanism of EPHA4-ephrin modulation by DCHS1 undefined

• It remains unknown how the DCHS1 ICD and its cleaved fragments biochemically couple to YAP phosphorylation, cytoskeletal scaffolds, and EPHA4 signaling to produce tissue-specific Hippo-dependent versus Hippo-independent outputs.
• Direct DCHS1 ICD interactome not mapped
• Mechanism switching between YAP-dependent and YAP-independent outputs unresolved